Poolbeg Pharma plc is a biopharmaceutical company committed to the development and commercialisation of innovative medicines that address critical unmet medical needs with a growing emphasis on rare and orphan diseases. We have built a robust development pipeline of ground breaking products and are focused on strategically commercialising approved and marketed drugs to fund the development of our robust pipeline of ground breaking products.

Industry Leading Team

We are led by a team dedicated to improving global health and with proven capabilities in identifying, acquiring, and accelerating assets through development and commercialisation.

Our team has been further strengthened by the appointment of three former members of the Amryt Pharma plc leadership team who bring a deep knowledge of the rare and orphan drug space.

Learn More
Meeting 768x426 1

High Impact Programmes

Our clinical programmes target diseases with a high unmet medical need including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist.

Our AI-led programmes leverage data from over 20 years of human challenge trials and have identified clinically relevant drug targets and treatments. This accelerates development timelines and enhances commercial appeal.

Learn More
High Impact Programmes

Investor Relations

Poolbeg is headquartered in London and is publicly traded on the London Stock Exchange & the OTC Markets in the US

AIM: POLB
OTCQB: POLBF

VISIT INVESTOR CENTRE